Arcturus Therapeutics (ARCT) holds $213M in cash against an enterprise value of roughly $21M — the market is pricing the clinical portfolio (ARCT-032 inhaled mRNA for cystic fibrosis, ARCT-810 for OTC deficiency, LUNAR delivery platform IP) at near-zero. On May 4, 2026 — three days before ARCT's Q1 earnings call — Vertex/Moderna discontinued VX-522, the only directly comparable inhaled mRNA CF program. Vertex CEO Reshma Kewalramani blamed the lipid nanoparticle delivery system.

Why "Vertex blamed LNP" corroborates ARCT rather than condemning it

VX-522 used Moderna's LNP chemistry. Kewalramani's exact attribution on the May 4 VRTX call: "tolerability issues...lung inflammation, like inflammatory response, probably response LNP deliver." LNPs optimized for systemic IM delivery have not historically tolerated chronic pulmonary administration — the record is consistent. Translate Bio's MRT5005 was abandoned in 2023 after 5 daily doses produced febrile and hypersensitivity reactions. VX-522 was paused May 2025, resumed September 2025 with undisclosed mitigations, terminated May 4, 2026 before completing its multi-ascending-dose phase. ReCode's RCT2100 Phase 2 protocol caps mRNA dosing at 4 weeks.

ARCT's LUNAR platform uses a chemically distinct delivery lipid family, validated through KOSTAIVE — the only approved self-amplifying mRNA vaccine globally (Japan 2023, EU 2025, UK 2026). ARCT-032 Cohort 4, a 12-week 20-patient continuous dosing protocol in Class I null-mutation CF patients, has dosed "well beyond one month" with no clinically worrisome safety signals. As of May 14, ARCT is the sole publicly-disclosed inhaled mRNA CF program with disclosed multi-week patient dosing. The cross-corroboration is the May 4 event: the competitor that failed used a different lipid family.

What else the Q1 call said

Cash $213.4M at March 31; Q1 burn $19.4M; runway guided "beyond Q2 2028" — a meaningful upgrade from FY2025's "at least 12 months." Wells Fargo $50M revolver terminated December 2025, releasing $55M restricted cash. CSL was conspicuously absent — zero mention by management, no analyst question, narrative pivoted to "rare disease clinical programs." Silence on active arbitration is lawyered posture, not a positive signal, but the cash runway means ARCT has time for the data to land. ARCT-810 (OTC deficiency) FDA Type C complete; clear pediatric pivotal path; EOP2 H2 2026.

What the market thinks — and where it's wrong

Dec 2026 ATM implied volatility — covering the binary catalyst window — is 80%. A small-cap biotech 7 months pre-binary readout would typically price 100-150%. Term structure is monotonically decreasing rather than humping at the catalyst; open interest is zero across all expirations. The options market has not repriced for Cohort 4.

The 28.2% short interest is positioned on the CSL/dilution narrative: KOSTAIVE US BLA indefinitely delayed by FDA October 2025, CSL $430M write-down February 2026, FY2025 collaboration revenue -51% YoY. That bear thesis is real but orthogonal to the post-May 4 sole-survivor argument. The counterparty selling on the dying-entity narrative likely hasn't connected the dots. Sell-side coverage is thin (3-4 analysts) with a $19.89 mean target, but every rating dates pre-May 4 — when a sell-side note finally publishes the VX-522 → ARCT connection, that note itself is a re-rate trigger.

Why the gap exists

The read-through has to be assembled, not read. The May 4 disclosure lived inside Vertex's $7B+ CFTR franchise call. ARCT pointedly did not name VX-522 on May 7 — a defensible choice given the open CSL arbitration, but it leaves the cross-corroboration unspoken. No sell-side note has published the connection. The dominant trading narrative since the February 2026 CSL write-down has been ARCT's bear story; the clinical platform thesis has been ignored.

Forward EV

Probability-weighted intrinsic value: $12.60 per share, +52% to spot over 7-8 months. Bull tail (clean Cohort 4 + efficacy signal + VRTX action): $25-35 at ≈13% probability. Bear tail (Cohort 4 safety failure): $2.50-5.00 at ≈30%. Forward σ ≈85% (crude — biotech binary), α/σ ≈0.6 in Sharpe units. Idio variance ≈96%; sector and style exposures negligible.

Risks (ranked)

1. Cohort 4 safety failure (≈30%). The honest steelman: VX-522 ran approximately two years before clinical inflammation manifested in patients. The exact dosing-week of failure has not been publicly disclosed, so ARCT being "beyond one month" is encouraging but not clean. If VX-522 was tolerated through week 4 and broke at weeks 8-12, ARCT's current position is materially less reassuring. We land at 30% rather than 40% because (a) ARCT's LUNAR chemistry has KOSTAIVE-validated chronic in-vivo evidence VX-522 lacked, (b) Cohort 2 produced clean 28-day patient data before Cohort 4 enrolled, (c) the Safety Monitoring Committee cleared 12-week expansion with no signals. Enrollment pause 8-K invalidates the thesis instantly. Floor: ≈$5 (cash + ARCT-810 residual).

2. CSL arbitration. Field-by-field termination is the modal outcome (worldview prediction 55%). Already mostly priced.

3. VRTX optionality is convergent but historically off-pattern. Vertex has acquired Semma ($950M, cell therapy), partnered CRISPR Therapeutics (gene editing), and partnered 4D Molecular (AAV gene therapy in CF). No precedent for an mRNA platform acquisition. Convergent motive ($13B cash, Class I CF coverage gap) is not pattern continuation. Conditional on clean Cohort 4 data, our base rate on VRTX action is perhaps 25-35% — license rather than acquire is the likelier path, and ReCode (private) is a competing target.

4. Dilution. ATM authority intact; 60M shares authorized vs 28.4M issued.

Catalysts

• ARCT C-suite Form 4 P-code purchases — particularly post-May 4
• ARCT Q2 2026 earnings — early August (interim Cohort 4 update possible)
• NACFC conference — October-November 2026 (CF Foundation Reach Study LCI normative data)
• ARCT-032 Cohort 4 12-week data readout — end-2026 (the binary)
• VRTX 8-K Item 1.01 — any time

What would change our mind

Bearish: Cohort 4 enrollment pause 8-K. Item 8.01 safety disclosure. VRTX announcing internal mRNA-CFTR replacement program. Dilutive raise >$30M. Public disclosure that VX-522 was tolerated through week 4 and broke at weeks 8-12 (would invert the survivor-bias balance).

More bullish: Coordinated C-suite Form 4 P-code purchases. VRTX 8-K Item 1.01 with ARCT counterparty. Interim Cohort 4 data showing FEV1 or LCI movement (not just safety). Sell-side note publishing the VX-522 → ARCT connection.

Evidence